Background: Various groups have called for a national system to monitor the quality of cancer care. The validity of cancer registry data for quality of cancer care has not been well studied. We investigated the validity of such information in the California Cancer Registry. Methods: We compared registry data associated with care with data abstracted from the medical records of patients diagnosed with breast cancer. We also calculated a quality score for each subject by determining the proportion of four evidencebased quality indicators that were met and then compared overall quality scores obtained from registry and medical record data. All statistical tests were two-sided. Results: Records of 304 patients were studied. Compared with the medical record data gold standard, the accuracy of registry data was higher for hospital-based services (sensitivity = 95.0% for mastectomy, 94.9% for lumpectomy, and 95.9% for lymph node dissection) than for ambulatory services (sensitivity = 9.8% for biopsy, 72.2% for radiation therapy, 55.6% for chemotherapy, and 36.2% for hormone therapy). On average, quality scores calculated from registry data were 11 percentage points (95% confidence interval [CI] = 9 to 13 percentage points, P<.001) lower than those calculated from medical record data. Quality scores calculated from registry data were 5 percentage points (95% CI = 3 to 7 percentage points) lower for patients with stage I breast cancer, 16 percentage points (95% CI = 12 to 20 percentage points) lower for patients with stage II breast cancer, and 20 percentage points (95% CI = 8 to 32 percentage points) lower for patients with stage III breast cancer than were corresponding scores calculated from medical record data (all P<.001). The greater difference in quality scores for stage II and III patients revealed that disease severity and setting of care affected the validity of registry data. Conclusions: Cancer registry data for quality measurement may not be valid for all care settings, but registries could provide the infrastructure for collecting data on the quality of cancer care. We urge that funding be increased to augment data
decade, a number of studies (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) have documented variations in the outcomes and patterns of care of cancer patients. Many of these studies (15) (16) (17) (18) (19) (20) rely on data reported by cancer registries.
Cancer registries collect data to determine incidence, to determine trends in various population groups, to plan epidemiologic research and cancer control, and to support health care planning (21) (22) (23) (24) (25) . The cancer registry system in the United States exists as multiple overlapping, hierarchical systems under different governing bodies (25) , and the systems have different purposes and speeds of reporting. Many hospitals maintain registries on cancer patients under their care and use data from these registries for certification by the American College of Surgeons or to meet state or federal requirements (26) . Because hospitals themselves are expected to support these data collection efforts, there is probably variability in the resources that different hospitals expend on registry activities. Consequently, the effort that individual hospital registries expend on data collection may vary greatly, and the accuracy of their data would be expected to reflect this variability.
Valid information about the care provided is a prerequisite to accurately determining quality of care. Although the completeness of cancer registry data for incident cancer cases is very high [e.g., 97% in the Surveillance, Epidemiology, and End Results (SEER)
1 Program (27) ], the validity of cancer registry data for the quality of cancer care has not been well studied. We conducted this study to evaluate the validity of California Cancer Registry data for measuring the quality of the initial treatment for breast cancer by comparing data in this registry with that of the medical record "gold standard."
METHODS
We compared the validity of data in the California Cancer Registry with that of the medical record gold standard for the following variables: breast biopsy, breast cancer surgery, lymph node dissection, radiation therapy, chemotherapy, hormone therapy, and American Joint Commission on Cancer (AJCC) stage (28) .
Case Identification and Sampling
We obtained outpatient medical records of a sample of patients with breast cancer from PacifiCare of California (Cypress, CA). Potential cases of breast cancer were identified by the health plan's quality improvement staff, who used an administrative data system to select all female enrollees with International Classification of Diseases, Version 9 (ICD-9) or Current Procedural Terminology (CPT) billing codes for breast cancer (174.*, 198.81, 233.0, 85. 4*, 19160, 19162, 19180, 19182, 19200, 19220, and 19240 , where * ‫ס‬ any digit from 0 to 9) from January 1992 through June 1996. The staff of the California Cancer Registry performed a probabilistic linkage of the identified cases in the health plan with breast cancer cases in the registry by using Social Security number, name, birth date, and address. After the California Cancer Registry "de-identified" the data, we received the linked data file. Three hundred sixty-three women had multiple entries, representing multiple diagnoses of breast cancer. We selected the first diagnosis occurring during the study period for inclusion or, for bilateral cancers occurring synchronously, the diagnosis of the more advanced cancer. From this database, we randomly sampled women diagnosed with breast cancer for the first time from 1993 through 1995 in Los Angeles County who were enrolled in PacifiCare on or before the date of diagnosis and during the entire period of follow-up for this study. Los Angeles County, California, has one of 10 registries that make up the California Cancer Registry and has been a part of the National Cancer Institute-funded SEER program since 1992 (29) . The SEER program is considered the gold standard for data quality among cancer registries around the world with a near complete case identification (98%) and a 95% annual rate of follow-up to determine survival (27, 30) . Limiting our study to cases from the Los Angeles County registry ensured that the registry data would be of the highest quality available.
Pursuit of Medical Records
Our goal was to obtain all medical record data for a sample of 300 patients. We used a professional copier service that worked with the health plan's quality improvement program to obtain a de-identified copy of the medical record for each patient. From their administrative files, PacifiCare identified the provider organization (i.e., an integrated medical group or an independent provider organization) that had a contract with the health plan to provide medical services for patients at the time of their diagnosis. The professional copier service then attempted to obtain the medical records for 1 year before diagnosis through 2 years after diagnosis from that provider organization. To be considered adequate, the provider organizations' medical record had to include a pathology report for at least one breast procedure and the notes of at least one physician providing care for the breast cancer episode (e.g., a surgeon, medical oncologist, or radiation oncologist) for at least 12 months after the date of diagnosis. If this information was not available, the medical record was searched for information regarding other providers that the patient had seen and the name of the facility where any procedures were performed. Medical records were then requested from the additional providers and facilities, in the following order: 1) medical oncologist, 2) radiation oncologist, 3) surgeon, and 4) hospital. If, in combination with the first record, the second record did not yield the information specified above, the next record was requested. This process was continued until the leads on possible records were exhausted. A case was considered "incomplete" if we did not find medical records from at least one physician providing care for breast cancer for at least 3 months after the date of diagnosis or documentation that treatment was completed within the time frame of available records. We excluded patients who were found not to have breast cancer after review of their medical records (in all cases, these patients had been diagnosed with lobular carcinoma in situ). The institutional review board of the University of California, Los Angeles, approved the study.
Medical Record Abstraction
Three research assistants (two medical students and a staff member with a bachelor of science degree in biology and several years of abstraction experience on other research studies) and an oncologist (J. Malin) abstracted each medical record by use of a chart abstraction instrument developed specifically for this study (available from the authors). We abstracted the medical record from 6 months before diagnosis through 12 months after diagnosis for information regarding the cancer diagnosis and evaluation, the characteristics and spread of the tumor, the initial cancer treatment, and the presence of comorbidity by use of the Charlson Comorbidity Index (30) . A physician (J. Malin) reviewed all medical records with questions about abstraction or coding. Interrater reliability was assessed among the four abstractors on a 5% sample of the medical records. Reliability of the variables describing the treatments received was excellent with a statistic of consistently greater than 0.80.
Statistical Analyses
Statistical analyses were performed with SAS software (version 6.12; SAS Institute, Cary, NC). We calculated the observed agreement, statistic, sensitivity, and specificity of the California Cancer Registry data compared with the medical record gold standard. To illustrate the importance of valid data when measuring quality of care, we used the following four quality indicators (QIs), grounded in the scientific literature with broad expert consensus, that could be determined from California Cancer Registry data: QI1 ‫ס‬ patients with stage I through III breast cancer should have definitive surgery; QI2 ‫ס‬ patients with stage I through III breast cancer should have a lymph node dissection; QI3 ‫ס‬ patients with stage I through III breast cancer treated with breast-conserving surgery should receive radiation therapy; and QI4 ‫ס‬ patients with stage II or III breast cancer should receive tamoxifen or chemotherapy.
We limited the eligibility for QI4, the quality indicator for adjuvant systemic therapy, to patients with stage II or III disease because, from 1993 through 1995, patients with tumors of 1-2 cm were just beginning to be considered for adjuvant therapy and consensus recommendations for this group were vague (31) (32) (33) . We compared the proportion of patients who had care that met the quality indicators in California Cancer Registry data with that in medical record data. We calculated an overall quality score for each subject by determining the proportion of quality indicators that were met relative to those for which patients were eligible. For example, if a patient had stage I breast cancer and a lumpectomy, she was eligible for the first three quality indicators (QI1-3). If she had a lumpectomy but no axillary lymph node dissection and then received radiation therapy and tamoxifen, she met only two of three possible quality indicators (even though she received tamoxifen). Because she did not meet the eligibility criteria established for QI3, her data for this indicator would not be counted in her quality score. Her quality score would then be 2/3 or 0.67. The individual quality scores were averaged to create an overall quality score for the sample. We then compared the quality of care as measured by the quality score calculated from California Cancer Registry data with that calculated from medical record data. To identify subgroups for which registry data might be less valid, we compared the difference in the quality scores determined from registry data and from medical record data for the following groups of patients: those with stage I, II, and III breast cancer; those younger than 70 years versus those 70 years old or older; white patients versus nonwhite patients; and those with comorbidity counts of 0, 1, and 2 or higher. We chose 70 years as our cut point for age because the literature on patterns of care in breast cancer suggests that patients older than 70 years are less likely to receive standard breast cancer treatment than are younger women (15, 16, 19, (33) (34) (35) . We used the 2 test to assess differences across categorical variables and the Student t test to assess differences for continuous variables. To explore statistical interaction effects on registry data validity, we modeled the effects of age, race, disease stage (stage I versus stages II and III), number of comorbidities, and the interaction terms for age × stage, race × stage, age × race, age × comorbidity, and race × comorbidity on the difference between quality scores determined from medical record data and from registry data. All statistical tests were two-sided.
RESULTS
Of 13 104 potential cases of breast cancer identified by PacifiCare of California, 7395 were matched with an entry in the California Cancer Registry, representing 7032 unique women with breast cancer (Fig. 1) . Excluded cases most likely represented "rule-out" diagnoses, cases of breast cancer diagnosed before 1988 (the year the California Cancer Registry was established), and diagnoses outside of California not captured by the California Cancer Registry. Limiting the sample to cases diagnosed from 1993 through 1995 while the patient was enrolled in PacifiCare left 2712 women. We attempted to obtain the medical records of 391 cases, randomly selected from the 658 health plan enrollees diagnosed in Los Angeles County from 1993 through 1995. Four cases were found to be ineligible because they had lobular carcinoma in situ, a preinvasive condition that does not require treatment. Of the 387 eligible cases, we obtained medical records for 304 (79%). Cases for which we could not obtain medical records did not appear essentially different from the study sample, according to California Cancer Registry data, although there was a trend for the cases on which medical records were not available or not complete to have less extensive surgery reported by the registry ( Compared with all breast cancer cases in Los Angeles County and California from 1993 through 1995, our sample was somewhat older and less ethnically diverse (Table 2 ). In the analytic sample, 88.1% of women were 50 years old or older compared with 75.2% in Los Angeles County and 76.1% statewide (P<.001 for the age distribution in the analytic sample as compared with those in Los Angeles County and California), reflecting the older patient population enrolled in PacifiCare of California, which has a Medicare contract. The analytic sample also had a lower proportion of ethnic minorities than did Los Angeles County (6.3% versus 10.9%, respectively, for black; 14.1% versus 15.0%, for Hispanic; 4.9% versus 7.9%, for Asian; all P ‫ס‬ .01). Because ethnic minorities are less likely to be insured (38, 39) , this difference was not surprising and again represented a bias of our sampling frame.
California Cancer Registry data were more accurate for hospital-based services than for ambulatory services when compared with the medical record gold standard (Table 3) . Agreement between California Cancer Registry data and medical record data was excellent for the type of surgery (94%) and the receipt of lymph node dissection (95%) ( ‫ס‬ 0.90 and 0.89, respectively), procedures generally performed in a hospital or hospital-based outpatient surgery center). Compared with medical record data, registry data were more accurate for hospitalbased services (sensitivity ‫ס‬ 95.0% for mastectomy, 94.9% for lumpectomy, and 95.9% for lymph node dissection) than for ambulatory services (sensitivity ‫ס‬ 9.8% for biopsy, 72.2% for radiation therapy, 55.6% for chemotherapy, and 36.2% for hormone therapy). The specificity of the California Cancer Registry data compared with the medical record data was 95% or greater for these procedures.
In contrast, the registry missed between 28% and 90% of services provided in the ambulatory setting (Table 3 ). The California Cancer Registry identified only 10 women (3.3%) as having received a breast biopsy examination, typically an officebased procedure, whereas 92 patients (30.3%) had documentation of a breast biopsy examination in their medical records.
Although there was good agreement between California Cancer Registry data and the medical record data regarding receipt of radiation therapy and chemotherapy ( ‫ס‬ 0.70 and 0.62, respectively), the registry failed to identify 28% and 44% of patients who received these treatments. The sensitivity of registry data for receipt of radiation therapy, which is often hospital-based and occurs immediately after surgery or chemotherapy, was 72.2%. The sensitivity of the registry for chemotherapy, which is also initiated immediately after surgery but is usually administered in a medical oncologist's office, was 55.6%. The sensitivity of the registry for hormone (i.e., tamoxifen) treatment, which is usually the last treatment initiated and is prescribed by a physician for a patient to take at home, was only 36.2%. However, when the registry data reported that a patient had received treatment, this treatment was generally confirmed by the medical record data, as indicated by a specificity of 98.8% for radiation therapy and chemotherapy and of 94.7% for hormone therapy. The stage of a patient is determined from the results of the breast surgery, lymph node dissection and analysis, and testing for the presence of distant metastases, and this determination often includes both hospital-based and ambulatory services. We found only moderate agreement between the stage reported by the registry and that reported in the medical record (82%, ‫ס‬ 0.73). Sensitivity of the registry data compared with the medical record data for stage was 80.6% for stage 0, 86.4% for stage I, 82.8% for stage II, 72.7% for stage III, and 41.7% for stage IV. The corresponding specificities were 99.6%, 93.6%, 93.1%, 98.3%, and 100.0%.
The accuracy of the California Cancer Registry did not appear to vary by age or race/ethnicity. The scores for each of the variables were not statistically significantly different for patients younger than 70 years compared with those 70 years and older or for nonwhite patients compared with white patients.
To illustrate the importance of valid data on the results of quality measurement, we compared the average percentage of patients meeting four quality indicators from California Cancer Registry data with that obtained from medical record data (Table  4) . Two of the quality indicators reflected hospital-based services (QI1 and QI2), and two reflected ambulatory services (QI3 and QI4). The percentages of patients whose care met the quality indicators for hospital-based services were not statisti- cally significantly different when calculated from registry data and medical record data. Virtually all patients, 99% (95% CI ‫ס‬ 98% to 100%), met the first quality indicator. For the second indicator, QI2, registry data indicated that 84% (95% CI ‫ס‬ 79% to 89%) of patients had received the care; medical record data indicated that 88% (95% CI ‫ס‬ 84% to 92%) had. However, the percentage of patients whose care appeared to meet the quality indicators for ambulatory services was statistically significantly underestimated by registry data. When California Cancer Registry data were used, only 63% (95% CI ‫ס‬ 54% to 72%) of patients appeared to have received the indicated radiation therapy after breast-conserving surgery (QI3). When medical record data were used, however, 85% (95% CI ‫ס‬ 79% to 91%) of patients appeared to have received such care. Similarly, 46% (95% CI ‫ס‬ 37% to 55%) of patients from registry data and 90% (95% CI ‫ס‬ 85% to 95%) of patients from medical record data appeared to receive the indicated adjuvant therapy (QI4).
Not surprisingly, the overall quality score (determined as a percentage of the four quality indicators) was lower when registry data were used than when medical record data were used (Table 5) . Variation was observed in quality scores with patient age, race, and comorbidity. Older patients had lower quality scores, regardless of data source, compared with younger patients. Patients aged 70 years and older had quality scores of 76 percentage points (95% CI ‫ס‬ 72 to 80 percentage points) with registry data and 87 percentage points (95% CI ‫ס‬ 83 to 91 percentage points) with medical record data, whereas patients aged younger than 70 years had scores of 85 percentage points (95% CI ‫ס‬ 81 to 89 percentage points) and 96 percentage points (95% CI ‫ס‬ 94 to 98 percentage points), respectively. It is interesting that nonwhite patients had higher quality scores than did white patients, regardless of data source. A difference of 11 percentage points (95% CI ‫ס‬ 9 to 13 percentage points; P<.001) was obtained in the quality score, or the overall percentage of quality indicators met, when values calculated from registry data (81 percentage points, 95% CI ‫ס‬ 36 to 126 percentage points) and from the gold standard medical record data (92 percentage points, 95% CI ‫ס‬ 59 to 130 percentage points) were compared (Table 5) . This difference was consistent regardless of the age and race of the patients. That is, even though variation was observed in the quality scores for patients according to their age and race, the quality score calculated from registry data was consistently about 10 percentage points lower than that calculated from medical record data. However, the difference was more marked when quality scores calculated from the two data sources for cases of stage I, II, and III breast cancer were compared (Table 5) . Although the quality score calculated from registry data was only 5 percentage points (95% CI ‫ס‬ 3 to 7 percentage points) lower than that obtained from the medical record for patients with stage I breast cancer, the quality score was on average 16 percentage points (95% CI ‫ס‬ 12 to 20 percentage points) lower for those with stage II, and 20 percentage points (95% CI ‫ס‬ 8 to 32 percentage points) lower for those with stage III (P<.001). The greater difference in quality scores for stage II and III patients revealed an important interaction between disease severity and setting of care that affected the validity of registry data: patients with a more advanced stage more often received treatment in the ambulatory setting that was less likely to be reported by the registry. By definition, stage I cases were only eligible for three of the four quality indicators, whereas the quality score for all stage II and III cases included a quality indicator for receipt of adjuvant therapy (Table 4 ; QI4). Recall that registry data about adjuvant therapy, which includes chemotherapy and tamoxifen and is generally provided in the ambulatory setting, had low validity. Interestingly, for patients with two or more comorbidities, no difference was observed in their quality scores for breast cancer care calculated from the two data sources. Patients with comorbidities were less likely to get any treatment for breast cancer beyond the initial surgery. Less outpatient treatment resulted in less bias in quality scores calculated from cancer registry data.
To explore the statistical interaction effects resulting from registry data validity, we modeled the effect of age, race, disease stage, number of comorbidities, and interaction terms for each of the covariates on the difference between the quality score determined from medical record data and that obtained from registry data. Race was not a statistically significant variable (P ‫ס‬ .17) and was dropped from the model. Of the interaction terms tested (age × race, age × stage, age × comorbidity, race × stage, and race × comorbidity), only age × stage was statistically significant. Our final model thus included age (<70 years old versus ജ70 years old), stage (stage I versus stages II and III), comorbidity (number of comorbidities from the Charlson Comorbidity Index), and an interaction term for age and stage ( Table 6 ). The model equation was as follows for the difference in quality score (⌬):
where QS MR ‫ס‬ the quality score calculated from medical records, and QS CCR ‫ס‬ the quality score calculated from the California Cancer Registry. The model predicts that, for a woman without clinically significant comorbidity who is 70 years old or older with stage I breast cancer, her quality score (percentage of quality indicators met) would be, on average, 4 percentage points (95% CI ‫ס‬ -1 to 9 percentage points) greater with medical record data than with registry data. If this same patient were in the group younger than 70 years, her predicted quality score would be 9 percentage points (95% CI ‫ס‬ 5 to 14 percentage points) greater from medical record data than from registry data. A woman with no clinically significant comorbidity and stage II or III breast cancer would be expected to have a quality score 22 percentage points (95% CI ‫ס‬ 16 to 27 percentage points) greater if she was 70 years old or older and 16 percentage points (95% CI ‫ס‬ 12 to 20 percentage points) greater if she was younger than 70 years old. Each additional comorbidity decreases the predicted difference in quality scores calculated from registry data compared with medical record data by 4 percentage points (95% CI ‫ס‬ -6 to 8 percentage points).
DISCUSSION
Compared with a medical record gold standard, we found that the validity of registry data on breast cancer treatment varied with the setting of care. Although the California Cancer Registry data were accurate for hospital-based services, its data did not accurately reflect the care that patients received in the ambulatory setting. In the California Cancer Registry, we identified 72% of the women who the medical record reported had definitely received radiation therapy, 56% of the women who the medical record indicated had received chemotherapy, and 36% of women who the medical record indicated had received tamoxifen, as indicated by the medical record. Our findings are similar to those reported by Bickell and Chassin (38) . They found that cancer registry data at three New York City hospitals, compared with data from a quality improvement project, could identify 58% of the patients who received radiation therapy and 27% of those who received chemotherapy or tamoxifen.
If providers or health plans are compared by the use of registry data, those with patients who are elderly or have more advanced disease would appear to be providing worse care because of the quality of the data. In addition, providers or health plans that provide more care in an ambulatory setting might between the medical record and the cancer registry was 82%, the number of cases for whom a difference in quality scores could be calculated is less than the number of cases for whom a quality score was determined using each data source.
§P<.001 for the quality score difference by stage groups. ¶P ‫ס‬ .04 for the quality score difference by comorbidity groups. , where QS ‫ס‬ quality score, MR ‫ס‬ medical record, and CCR ‫ס‬ California Cancer Registry. A positive value indicates that the quality scores calculated from medical record data were higher than those calculated from registry data. A negative score indicates that quality scores calculated from registry data were higher than those calculated from medical record data. The following variables were included for model selection: age, race, stage, comorbidity, and interaction terms for age × stage, race × stage, age × race, age × comorbidity, and race × comorbidity.
‡The age of <70 y is referent. §Stage I is referent.
appear to have lower quality scores. Reporting the quality of care derived from data with such validity problems could anger providers and seriously undermine public confidence in this process. We conducted our study by use of a sample of patients diagnosed with breast cancer from a California health maintenance organization (HMO). Although our methods permitted access to the outpatient medical records for more than 80% of the sampled cases, it posed several limitations for the study. First, the resulting study sample reflected the characteristics of the patients enrolled in the HMO and was, therefore, somewhat older and less ethnically diverse than the overall population of women diagnosed with breast cancer in Los Angeles. Second, it is possible that the HMO's practice of contracting with medical groups and hospitals tended to exclude hospitals with limited resources, thereby limiting our ability to detect differences in the validity of cancer registry data. Third, cases were selected for this study by linking data from the California Cancer Registry with a file of women identified by the health plan as having ICD-9 and CPT codes for breast cancer. This protocol resulted in cases without a breast cancer claim being excluded from our study. If our goal was to describe the quality of care of women in this health plan, this exclusion could be an important bias. However, the impact of this bias on an evaluation of the validity of the registry data is likely to be minimal.
The results of this study highlight the importance of using data that are valid across clinical settings and time to measure quality of care. We found that, compared with medical record data, the validity of registry data varied with the setting of care, being less accurate for ambulatory services than for hospitalbased care. Furthermore, the setting of care varied with patient characteristics, another source of bias in measurement of quality of care. As cancer care is increasingly focused in the outpatient setting, the use of data that are not valid for ambulatory services would substantially undercut efforts to accurately measure the quality of care. For example, if these data were used for surveillance of the quality of breast cancer care, the quality of ambulatory services would be underestimated. If used to identify areas for quality improvement, resources could be diverted away from the area most in need of improvement. If such data were used to hold providers accountable for the quality of their care, for example, by requiring that a certain standard of quality be met to be allowed to bill Medicare, some providers could inappropriately be penalized (5) .
In addition to improving the accuracy of data on ambulatory services, a few other modifications of registry procedures are needed for registry data to be used for quality measurement. First, registries would need to augment their data collection efforts to include information about a patient's comorbidities; comorbidity data are necessary for valid measurement of the process and outcomes of care (39) . Second, registries may need to expand their data collection efforts to provide greater clinical detail (e.g., dosage of chemotherapy drugs and number of treatments). Research is ongoing to determine how much clinical detail is needed to make valid assessments of the quality of care. Third, the time between case ascertainment by the hospital registries and data availability from the central registries, typically 2 years (29) , would need to be reduced because more timely data are needed for use by stakeholders and policy makers evaluating the quality of care.
In spite of the challenges described, cancer registries have tremendous potential for quality measurement. Because of their regulatory authority, cancer registries are uniquely situated to identify a population-based sample of cancer patients, and they are still the best candidates to provide the infrastructure for measuring the quality of cancer care. One approach to improving the accuracy of cancer registry data for quality measurement is to augment registry data with administrative data (40) (41) (42) (43) , such as SEER data augmented with Medicare claims data (44, 45) . However, this approach has caveats that limit its application for any national effort to monitor quality of care. First, administrative data have limited clinical detail. Second, administrative data are not necessarily accurate and would need to be validated (46) . Third, because of the fragmented nature of the U.S. health care system, no administrative database provides population-wide data. A database pieced together from various sources of administrative data for different cohorts of patients would be fraught with many problems. It is likely that the accuracy of such data would vary tremendously and that, as in this study, such data could interact with patient characteristics, setting of care, and other structural variables (e.g., type of health plan).
Further research is needed to explore novel strategies to obtain population-based data on quality of cancer care that would not require detailed data collection on every patient. Although claims data are not a panacea, if validated and found to be accurate, such data could be used when available. This procedure would allow resources for more detailed medical record review to be focused on those quality measures for which registry and claims data fall short. Another strategy would be to perform more detailed data collection (i.e., abstraction of the ambulatory medical records or patient surveys) on a sample of patients and then to use standard statistical techniques to impute the quality score for the entire population.
If registries were to collect additional primary data and systematically review outpatient medical records (as was done in this study) or survey patients about the medical care they received, the additional cost would be roughly $150 million to $250 million annually. In contrast, current budgets are approximately $34 million per year for the National Program of Cancer Registries, $22 million per year for SEER, and $1.2 million per year for the National Cancer Data Base; however, the costs associated with data collection are borne by the reporting facilities (47) . Unless central registry organizations (e.g., SEER, National Program of Cancer Registries, or the California Cancer Registry) assume a more active role in data collection, the costs of additional data collection would likely be borne by the reporting hospital registries and passed on to the purchasers of health care. Although this amount is a substantial investment, this amount is only about 0.2% of the estimated overall annual costs for cancer of $107 billion (of which direct medical costs are $37 billion) (48, 49) . This value is well within the range of investment in quality assessment and improvement made by other sectors of the economy, reported to be between 2% and 10% of total sales (50, 51) . Accurate data on the quality of cancer care are urgently needed. Health care purchasers and policy makers should consider investing in our cancer registry system to obtain these data.
